Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash to Debt 0.05
AGN's Cash to Debt is ranked lower than
97% of the 692 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.66 vs. AGN: 0.05 )
Ranked among companies with meaningful Cash to Debt only.
AGN' s 10-Year Cash to Debt Range
Min: 0.02  Med: 0.61 Max: 43.62
Current: 0.05
0.02
43.62
Equity to Asset 0.51
AGN's Equity to Asset is ranked lower than
67% of the 551 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.63 vs. AGN: 0.51 )
Ranked among companies with meaningful Equity to Asset only.
AGN' s 10-Year Equity to Asset Range
Min: 0.25  Med: 0.63 Max: 0.93
Current: 0.51
0.25
0.93
F-Score: 3
Z-Score: 1.14
M-Score: -1.42
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 6/10

vs
industry
vs
history
Operating margin (%) -12.28
AGN's Operating margin (%) is ranked lower than
81% of the 652 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.76 vs. AGN: -12.28 )
Ranked among companies with meaningful Operating margin (%) only.
AGN' s 10-Year Operating margin (%) Range
Min: -21.33  Med: 13.94 Max: 37.1
Current: -12.28
-21.33
37.1
Net-margin (%) -15.29
AGN's Net-margin (%) is ranked lower than
83% of the 652 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.85 vs. AGN: -15.29 )
Ranked among companies with meaningful Net-margin (%) only.
AGN' s 10-Year Net-margin (%) Range
Min: -22.48  Med: 9.27 Max: 35.15
Current: -15.29
-22.48
35.15
ROE (%) -7.55
AGN's ROE (%) is ranked lower than
76% of the 677 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.87 vs. AGN: -7.55 )
Ranked among companies with meaningful ROE (%) only.
AGN' s 10-Year ROE (%) Range
Min: -23.54  Med: 7.99 Max: 22.08
Current: -7.55
-23.54
22.08
ROA (%) -3.81
AGN's ROA (%) is ranked lower than
74% of the 697 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.99 vs. AGN: -3.81 )
Ranked among companies with meaningful ROA (%) only.
AGN' s 10-Year ROA (%) Range
Min: -13.02  Med: 4.60 Max: 19.77
Current: -3.81
-13.02
19.77
ROC (Joel Greenblatt) (%) -53.21
AGN's ROC (Joel Greenblatt) (%) is ranked lower than
81% of the 694 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 11.80 vs. AGN: -53.21 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
AGN' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -37.89  Med: 32.56 Max: 107.33
Current: -53.21
-37.89
107.33
Revenue Growth (3Y)(%) 17.90
AGN's Revenue Growth (3Y)(%) is ranked higher than
78% of the 534 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.80 vs. AGN: 17.90 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
AGN' s 10-Year Revenue Growth (3Y)(%) Range
Min: 6.4  Med: 17.60 Max: 40.5
Current: 17.9
6.4
40.5
EBITDA Growth (3Y)(%) -3.70
AGN's EBITDA Growth (3Y)(%) is ranked lower than
64% of the 476 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.80 vs. AGN: -3.70 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
AGN' s 10-Year EBITDA Growth (3Y)(%) Range
Min: -4.4  Med: 7.60 Max: 52.9
Current: -3.7
-4.4
52.9
» AGN's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q2 2014

AGN Guru Trades in Q2 2014

First Eagle Investment 30,000 sh (New)
Jim Chanos 45,300 sh (New)
Paul Singer 281,700 sh (New)
Kyle Bass 14,800 sh (New)
Louis Moore Bacon 60,000 sh (New)
First Eagle Investment 706,833 sh (New)
Andreas Halvorsen 803,369 sh (New)
Eric Mindich 901,000 sh (New)
Richard Perry 1,667,625 sh (New)
John Paulson 5,602,000 sh (New)
Bill Nygren 0 sh (+9999.00%)
Bill Ackman 28,878,538 sh (+4733.79%)
Louis Moore Bacon 47,348 sh (+846.39%)
Jana Partners 2,654,328 sh (+194.31%)
Jim Simons 416,395 sh (+153.20%)
Leon Cooperman 619,919 sh (+134.74%)
Paul Tudor Jones 101,500 sh (+90.79%)
George Soros 63,831 sh (+82.37%)
Eric Mindich 692,000 sh (+38.40%)
Jim Simons 507,725 sh (+26.32%)
Mario Gabelli 36,165 sh (+15.31%)
Andreas Halvorsen 1,207,824 sh (+10.65%)
Steve Mandel 2,478,628 sh (+4.22%)
Mario Gabelli 131,198 sh (+3.37%)
John Paulson 300,000 sh (unchged)
Daniel Loeb 2,500,000 sh (unchged)
John Griffin 1,735,000 sh (unchged)
Dodge & Cox 3,564 sh (unchged)
Steven Cohen 25,000 sh (unchged)
Steven Cohen 371,500 sh (unchged)
Bill Ackman 28,878,638 sh (unchged)
Jeremy Grantham Sold Out
Ray Dalio Sold Out
Francis Chou Sold Out
Diamond Hill Capital Sold Out
Joel Greenblatt Sold Out
Private Capital 172,284 sh (-1.53%)
Pioneer Investments 804,629 sh (-6.83%)
Ken Fisher 6,183 sh (-7.51%)
Vanguard Health Care Fund 3,359,667 sh (-7.89%)
RS Investment Management 845,397 sh (-10.03%)
Jeremy Grantham 973,051 sh (-11.68%)
Joel Greenblatt 16,281 sh (-13.60%)
Scott Black 48,858 sh (-28.03%)
Ken Heebner 370,000 sh (-41.27%)
Pioneer Investments 256,641 sh (-58.66%)
Paul Tudor Jones 2,900 sh (-70.96%)
» More
Q3 2014

AGN Guru Trades in Q3 2014

Bernard Horn 20,689 sh (New)
Joel Greenblatt 8,180 sh (New)
Larry Robbins 1,717,858 sh (New)
Dodge & Cox 4,025 sh (New)
Steven Cohen 102,900 sh (+311.60%)
John Paulson 1,062,200 sh (+254.07%)
Andreas Halvorsen 2,279,736 sh (+183.77%)
Vanguard Health Care Fund 8,555,596 sh (+154.66%)
George Soros 149,885 sh (+134.82%)
Andreas Halvorsen 2,550,336 sh (+111.15%)
Eric Mindich 1,683,251 sh (+86.82%)
Mario Gabelli 58,056 sh (+60.53%)
Eric Mindich 859,000 sh (+24.13%)
Daniel Loeb 2,875,000 sh (+15.00%)
Leon Cooperman 706,472 sh (+13.96%)
First Eagle Investment 740,675 sh (+4.79%)
John Griffin 1,735,000 sh (unchged)
Pioneer Investments 838,740 sh (unchged)
Pioneer Investments 139,359 sh (unchged)
Steve Mandel 2,478,628 sh (unchged)
Bill Ackman 28,878,538 sh (unchged)
Bill Ackman 28,878,638 sh (unchged)
Kyle Bass Sold Out
Richard Perry Sold Out
Ken Heebner Sold Out
Paul Singer Sold Out
Paul Tudor Jones 101,193 sh (-0.30%)
Ken Fisher 6,015 sh (-2.72%)
Private Capital 167,468 sh (-2.80%)
John Paulson 5,377,200 sh (-4.01%)
Jana Partners 2,514,701 sh (-5.26%)
Mario Gabelli 123,938 sh (-5.53%)
Jeremy Grantham 900,754 sh (-7.43%)
Scott Black 45,177 sh (-7.53%)
Dodge & Cox 3,264 sh (-8.42%)
Paul Tudor Jones 2,300 sh (-20.69%)
Steven Cohen 274,900 sh (-26.00%)
RS Investment Management 550,630 sh (-34.87%)
Louis Moore Bacon 28,636 sh (-39.52%)
Louis Moore Bacon 31,870 sh (-46.88%)
Jim Simons 193,595 sh (-53.51%)
Joel Greenblatt 5,670 sh (-65.17%)
Jim Chanos 15,330 sh (-66.16%)
First Eagle Investment 10,000 sh (-66.67%)
Jim Simons 128,162 sh (-74.76%)
» More
Q4 2014

AGN Guru Trades in Q4 2014

Diamond Hill Capital 2,966 sh (New)
Larry Robbins 629,647 sh (New)
Daniel Loeb 400,000 sh (New)
Paul Singer 992,887 sh (New)
George Soros 494,786 sh (New)
First Eagle Investment 634,476 sh (+6244.76%)
Jim Simons 454,162 sh (+254.37%)
Paul Tudor Jones 6,797 sh (+195.52%)
George Soros 321,214 sh (+114.31%)
Andreas Halvorsen 4,585,892 sh (+79.82%)
Jeremy Grantham 1,464,872 sh (+62.63%)
First Eagle Investment 1,176,582 sh (+58.85%)
Jim Simons 297,860 sh (+53.86%)
John Paulson 1,560,601 sh (+46.92%)
Leon Cooperman 943,572 sh (+33.56%)
Daniel Loeb 3,450,000 sh (+20.00%)
John Paulson 6,370,000 sh (+18.46%)
Larry Robbins 1,841,869 sh (+7.22%)
Pioneer Investments 887,293 sh (+5.79%)
Vanguard Health Care Fund 8,795,896 sh (+2.81%)
Eric Mindich 1,705,933 sh (+1.35%)
First Eagle Investment 60 sh (unchged)
Bernard Horn 20,689 sh (unchged)
Dodge & Cox 3,264 sh (unchged)
Bill Ackman 26,635,978 sh (unchged)
Bill Ackman 26,635,978 sh (unchged)
Joel Greenblatt Sold Out
Jim Chanos Sold Out
Steve Mandel Sold Out
Ken Fisher 5,972 sh (-0.71%)
Private Capital 166,197 sh (-0.76%)
John Griffin 1,625,000 sh (-6.34%)
Bill Ackman 26,635,978 sh (-7.77%)
Scott Black 41,091 sh (-9.04%)
Andreas Halvorsen 1,966,112 sh (-13.76%)
Dodge & Cox 3,293 sh (-18.19%)
RS Investment Management 414,013 sh (-24.81%)
Pioneer Investments 96,064 sh (-31.07%)
Jana Partners 1,718,804 sh (-31.65%)
Mario Gabelli 69,780 sh (-43.70%)
Louis Moore Bacon 16,374 sh (-48.62%)
Mario Gabelli 26,890 sh (-53.68%)
Eric Mindich 332,850 sh (-61.25%)
Louis Moore Bacon 7,666 sh (-73.23%)
Joel Greenblatt 945 sh (-83.33%)
Steven Cohen 21,900 sh (-92.03%)
Paul Tudor Jones 2,700 sh (-97.33%)
Steven Cohen 1,500 sh (-98.54%)
» More
Q1 2015

AGN Guru Trades in Q1 2015

Steve Mandel 1,832,314 sh (New)
Julian Robertson 72,500 sh (New)
Lee Ainslie 316,188 sh (New)
Signature Select Canadian Fund 10,600 sh (New)
Bill Ackman 1,348,358 sh (New)
Ken Fisher 3,233 sh (New)
Jeremy Grantham 263,619 sh (New)
Pioneer Investments 592,904 sh (+517.20%)
Louis Moore Bacon 31,216 sh (+307.20%)
John Paulson 5,640,788 sh (+261.45%)
Steven Cohen 3,783 sh (+152.20%)
Diamond Hill Capital 4,100 sh (+38.23%)
First Eagle Investment 1,573,572 sh (+33.74%)
Andreas Halvorsen 6,105,536 sh (+33.14%)
Mario Gabelli 35,151 sh (+30.72%)
George Soros 417,367 sh (+29.93%)
Larry Robbins 1,982,709 sh (+7.65%)
Daniel Loeb 3,575,000 sh (+3.62%)
Daniel Loeb 3,575,000 sh (+3.62%)
Vanguard Health Care Fund 9,038,107 sh (+2.75%)
Bernard Horn 20,689 sh (unchged)
Jim Simons Sold Out
First Eagle Investment Sold Out
Mario Gabelli Sold Out
Ken Fisher Sold Out
Dodge & Cox Sold Out
Pioneer Investments Sold Out
Jim Simons Sold Out
Bill Ackman Sold Out
John Paulson Sold Out
Steven Cohen Sold Out
Larry Robbins Sold Out
George Soros Sold Out
Paul Singer Sold Out
Joel Greenblatt Sold Out
Paul Tudor Jones Sold Out
Jeremy Grantham Sold Out
Daniel Loeb Sold Out
Louis Moore Bacon Sold Out
Eric Mindich Sold Out
Eric Mindich Sold Out
Andreas Halvorsen Sold Out
Bill Ackman Sold Out
Leon Cooperman 933,475 sh (-1.07%)
Scott Black 39,451 sh (-3.99%)
Private Capital 158,852 sh (-4.42%)
Jana Partners 1,621,852 sh (-5.64%)
RS Investment Management 385,566 sh (-6.87%)
John Griffin 1,466,000 sh (-9.78%)
Paul Tudor Jones 2,200 sh (-18.52%)
Dodge & Cox 1,602 sh (-51.35%)
» More
» Details

Insider Trades

Latest Guru Trades with AGN

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Preferred stocks of Allergan PLC

SymbolPriceYieldDescription
AGNPRA1056.431.295 1/2 % Cum.Conv.Pref.Shs 2015-1.3.18 Series -A-

Top Ranked Articles about Allergan PLC

Julian Robertson Adds 16 New Stakes to Portfolio
As the founder of one of the earliest hedge funds, Julian Robertson (Trades, Portfolio) is a pioneer in the world of investing. Robertson made 16 new buys in the first quarter, two of which were significant enough to join the 10 most valuable stakes in his portfolio. Now retired, Robertson invests in hedge funds that are often run by his former employees. Read more...
Pioneer Investments Sells Stakes in Allergan, Xilinx in First Quarter
On its website, Pioneer Investments (Trades, Portfolio) assures visitors that its goal is “to offer concrete investment solutions that satisfy real investment needs,” and it claims that its “time-tested” approach to investing “is supported by in-depth research and analysis as well as expert portfolio and risk management.” Read more...
Ruane, Cunniff & Goldfarb Inc Comments on Valeant
A topic many shareholders and clients wanted to discuss with us in 2014 was Valeant (VRX). It is the largest holding in Sequoia by far. One could argue Valeant wasted much of the year on a quixotic effort to buy Allergan (AGN), maker of Botox. Allergan had no interest in being acquired and fought a vicious and savvy public relations campaign to portray Valeant as unworthy of marriage to such a prized catch. In the end, Allergan found a suitor more to its liking in Actavis (ACT), and Actavis agreed to pay a substantially higher price than Valeant had offered. Read more...
Ackman's Pershing Square Now Available To The Public
Bill Ackman’s Pershing Square Holdings started trading on the Euronext Amsterdam under the symbol “PSH” on October 13. Daniel Loeb had a similar IPO in 2007 on the London Stock Exchange with his fund, Third Point Offshore (LSE:TPOU, LSE:TPOG, TPNTF). The goal of the IPO is to raise permanent capital to help the activist investor maintain his positions in target companies during times of turbulence. If too many investors have redemption requests in the hedge fund, the manager will not be able to maintain a position of control over all of the companies in the portfolio. Read more...
Bill Ackman's Midas Touch
Outside the investment community, the name of Bill Ackman (Trades, Portfolio) of Pershing Square might not raise as many eyebrows as the name of a guru like Warren Buffett (Trades, Portfolio), but Ackman’s track record is still impressive. He seems to have the Midas touch, even more of one than many of the gurus followed by GuruFocus. Read more...

Ratios

vs
industry
vs
history
Forward P/E 14.10
AGN's Forward P/E is ranked higher than
81% of the 244 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 23.58 vs. AGN: 14.10 )
Ranked among companies with meaningful Forward P/E only.
N/A
P/B 1.84
AGN's P/B is ranked higher than
75% of the 679 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.57 vs. AGN: 1.84 )
Ranked among companies with meaningful P/B only.
AGN' s 10-Year P/B Range
Min: 1.08  Med: 1.75 Max: 5.9
Current: 1.84
1.08
5.9
P/S 5.22
AGN's P/S is ranked lower than
63% of the 661 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.54 vs. AGN: 5.22 )
Ranked among companies with meaningful P/S only.
AGN' s 10-Year P/S Range
Min: 0.99  Med: 1.83 Max: 5.37
Current: 5.22
0.99
5.37
PFCF 38.11
AGN's PFCF is ranked higher than
56% of the 289 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 44.65 vs. AGN: 38.11 )
Ranked among companies with meaningful PFCF only.
AGN' s 10-Year PFCF Range
Min: 6.64  Med: 14.11 Max: 46.2
Current: 38.11
6.64
46.2
POCF 32.27
AGN's POCF is ranked lower than
54% of the 399 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 28.21 vs. AGN: 32.27 )
Ranked among companies with meaningful POCF only.
AGN' s 10-Year POCF Range
Min: 5.97  Med: 11.74 Max: 33.27
Current: 32.27
5.97
33.27
Current Ratio 1.44
AGN's Current Ratio is ranked lower than
73% of the 596 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.29 vs. AGN: 1.44 )
Ranked among companies with meaningful Current Ratio only.
AGN' s 10-Year Current Ratio Range
Min: 1.31  Med: 2.95 Max: 9.8
Current: 1.44
1.31
9.8
Quick Ratio 1.03
AGN's Quick Ratio is ranked lower than
74% of the 596 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.69 vs. AGN: 1.03 )
Ranked among companies with meaningful Quick Ratio only.
AGN' s 10-Year Quick Ratio Range
Min: 0.78  Med: 2.06 Max: 8.82
Current: 1.03
0.78
8.82
Days Inventory 121.45
AGN's Days Inventory is ranked lower than
54% of the 616 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 113.37 vs. AGN: 121.45 )
Ranked among companies with meaningful Days Inventory only.
AGN' s 10-Year Days Inventory Range
Min: 107.12  Med: 128.32 Max: 216.83
Current: 121.45
107.12
216.83
Days Sales Outstanding 99.54
AGN's Days Sales Outstanding is ranked lower than
69% of the 589 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 72.51 vs. AGN: 99.54 )
Ranked among companies with meaningful Days Sales Outstanding only.
AGN' s 10-Year Days Sales Outstanding Range
Min: 38.55  Med: 58.25 Max: 103.03
Current: 99.54
38.55
103.03

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield 0.10
AGN's Dividend Yield is ranked lower than
97% of the 608 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.29 vs. AGN: 0.10 )
Ranked among companies with meaningful Dividend Yield only.
AGN' s 10-Year Dividend Yield Range
Min: 0.08  Med: 0.32 Max: 0.63
Current: 0.1
0.08
0.63
Yield on cost (5-Year) 0.10
AGN's Yield on cost (5-Year) is ranked lower than
97% of the 626 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.34 vs. AGN: 0.10 )
Ranked among companies with meaningful Yield on cost (5-Year) only.
AGN' s 10-Year Yield on cost (5-Year) Range
Min: 0.08  Med: 0.32 Max: 0.63
Current: 0.1
0.08
0.63
Share Buyback Rate -20.20
AGN's Share Buyback Rate is ranked lower than
85% of the 432 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: -2.40 vs. AGN: -20.20 )
Ranked among companies with meaningful Share Buyback Rate only.
AGN' s 10-Year Share Buyback Rate Range
Min: 5.5  Med: -3.30 Max: -20.2
Current: -20.2

Valuation & Return

vs
industry
vs
history
Price/Projected FCF 1.28
AGN's Price/Projected FCF is ranked higher than
81% of the 315 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.05 vs. AGN: 1.28 )
Ranked among companies with meaningful Price/Projected FCF only.
AGN' s 10-Year Price/Projected FCF Range
Min: 0.59  Med: 1.13 Max: 3.29
Current: 1.28
0.59
3.29
Price/Median PS Value 2.84
AGN's Price/Median PS Value is ranked lower than
85% of the 608 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.36 vs. AGN: 2.84 )
Ranked among companies with meaningful Price/Median PS Value only.
AGN' s 10-Year Price/Median PS Value Range
Min: 0.67  Med: 1.35 Max: 5.37
Current: 2.84
0.67
5.37
Earnings Yield (Greenblatt) (%) -1.51
AGN's Earnings Yield (Greenblatt) (%) is ranked lower than
74% of the 698 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.80 vs. AGN: -1.51 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
AGN' s 10-Year Earnings Yield (Greenblatt) (%) Range
Min: -1.53  Med: 6.50 Max: 11.4
Current: -1.51
-1.53
11.4
Forward Rate of Return (Yacktman) (%) 8.71
AGN's Forward Rate of Return (Yacktman) (%) is ranked higher than
54% of the 307 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.25 vs. AGN: 8.71 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) (%) only.
AGN' s 10-Year Forward Rate of Return (Yacktman) (%) Range
Min: -3.7  Med: 7.90 Max: 16.5
Current: 8.71
-3.7
16.5

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Specialty & Generic
Compare:TKPYY, TEVA, FRX, MRX, ESALF » details
Traded in other countries:A60.Germany, AGN N.Mexico,
Actavis PLC, formerly known as Actavis Limited was incorporated in Ireland on May 16, 2013. It is an integrated specialty pharmaceutical company engaged in development, manufacturing, marketing, sale and distribution of generic, branded generic, brand name, biosimilar and over-the-counter pharmaceutical products. It also develops and out-license generic pharmaceutical products in Europe through its Medis third-party business. It operates in three segments, Actavis Pharma, Actavis Specialty Brands and Anda Distribution. The Actavis Pharma segment includes off-patent pharmaceutical products that are therapeutically equivalent to proprietary products. The Actavis Specialty Brands segment includes patent-protected products and certain trademarked off-patent products that the Company sells and markets as brand pharmaceutical products. The Anda Distribution segment distributes generic and brand pharmaceutical products manufactured by third parties, as well as by the Company to independent pharmacies, pharmacy chains, pharmacy buying groups and physicians' offices. It competes with generic manufacturers of pharmaceutical products. It is subject to extensive, complex and evolving regulation by the federal government, the FDA, and to a lesser extent, by the U.S. Drug Enforcement Administration Occupational Safety and Health Administration and state government agencies, as well as by various regulatory agencies in foreign countries where its products or product candidates are being manufactured and/or marketed. The Federal Food, Drug and Cosmetic Act, the Controlled Substances Act and other federal statutes and regulations govern or influence the testing, manufacturing, packing, labeling, storing, record keeping, safety, approval, advertising, promotion, sale and distribution of its products.
» More Articles for AGN

Headlines

Articles On GuruFocus.com
John Griffin Shows Stake in Trendy Fitbit Inc. Jun 30 2015 
Acquisition in the Health Care Industry Increased Volatility Jun 27 2015 
Julian Robertson Adds 16 New Stakes to Portfolio Jun 23 2015 
Smart Guru John Paulson Bullish on Actavis Jun 18 2015 
Leith Wheeler Investment Funds First Quarter 2015 Review Jun 15 2015 
Activist Hedge Fund Manager Has Strong Focus on Health Care Stocks Jun 11 2015 
My Top 3 Pharma Stock Picks Jun 09 2015 
Leon Cooperman's Top Holdings Look Attractive Jun 09 2015 
10 Reasons Why Growth Stocks Can Be Appropriate for Retired Investors Jun 04 2015 
John Paulson's First-Quarter Moves Alter Largest And Most Valuable Stakes Jun 01 2015 

More From Other Websites
How much will you spend this July 4th? Jul 02 2015
Top Takeaways From BMO's Specialty Pharma Day Jul 01 2015
Allergan and Valeant: Who'll See the Bigger Benefit from Irritable Bowels? Jul 01 2015
Willis-Towers Watson: A Merger of Equals—Not Exactly Jun 30 2015
A New Rider in the Perrigo, Mylan, Teva Merger Merry-Go-Round Jun 30 2015
Allergan to Host Second Quarter 2015 Earnings Conference Call and Webcast Jun 29 2015
Billionaires Cooperman and Larry Robbins Are Piling Into These Stocks Jun 29 2015
Billionaire Halvorsen and John Lykouretzos Are Betting On The Same Stocks Jun 29 2015
5 Rocket Stocks to Sidestep the Greek Drama Jun 29 2015
Eli Lilly Wins Alimta Patent Lawsuit in the UK, Shares Up - Analyst Blog Jun 26 2015
Zoetis Loses All Of Thursday's Spike On Valeant Buzz Jun 26 2015
Horizon Pharma Seen In Deal-Making Mode Jun 26 2015
20 Biotech and Healthcare Stocks The Richest Hedge Fund Billionaires Are Buying And Selling Now Jun 26 2015
Valeant, Zoetis Shares in the Dog House on Takeout Speculation Jun 26 2015
John Paulson riding health-care wave with new fund Jun 26 2015
Cramer's Stop Trading: Intel & Horizon Pharma Jun 26 2015
Cramer's Mad Dash: Finish Line's victory lap Jun 26 2015
Valeant Pharmaceuticals And Zoetis: A True Mega Deal Is On The Horizon Jun 26 2015
Third Point and Senator Investment Are Investing In The Same Stocks Jun 25 2015
Eli Lilly Wins Alimta Patent Case in U.K. Jun 25 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK